Autonomix Medical, Inc. (AMIX) AI Stock Analysis

• Market Cap: $5.63M
• Dividend Yield: N/A
• Average Volume (3M): 456.51K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.04
• Revenue Growth: N/A
• EPS Growth: 65.72%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -12.53
• Shares Outstanding: 6,194,147
• 10 Day Avg. Volume: 742,337
• 30 Day Avg. Volume: 456,513
• PEG Ratio: <0.01
• Price to Book (P/B): 0.38
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.37
• Enterprise Value/Market Cap: 1.70
• Enterprise Value/Revenue: 111.24
• Enterprise Value/Gross Profit: 239.17
• Enterprise Value/Ebitda: -0.81
• 1Y Price Target: $5.00
• Price Target Upside: 525.00% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: ―

Autonomix Medical, Inc. struggles with severe financial performance issues due to zero revenue and negative cash flow, despite low debt levels. Technical analysis suggests some short-term momentum, but a longer-term downtrend persists. Valuation is significantly impacted by negative earnings and no dividend yield. Positive trial outcomes present a potential opportunity but are insufficient to offset the substantial financial challenges.

Positive Factors

Patent Grant

The new patent strengthens Autonomix's intellectual property portfolio, enhancing its competitive edge in medical device innovation and potentially expanding its market reach.

Positive Trial Outcomes

Successful trial results could lead to expanded applications and market opportunities, improving long-term growth prospects by addressing unmet medical needs.

Warrant Exercise

The warrant exercise provides additional capital, bolstering financial stability and supporting ongoing R&D efforts, which is crucial for future growth and innovation.

Negative Factors

Zero Revenue

Lack of revenue generation is a critical concern, indicating challenges in monetizing products and achieving sustainable growth, which could impact long-term viability.

Negative Cash Flow

Negative cash flow highlights operational inefficiencies and reliance on external financing, posing risks to financial health and limiting strategic flexibility.

Reliance on Financing

Dependence on external financing can lead to vulnerability if funding becomes scarce, affecting the company's ability to sustain operations and invest in growth initiatives.

Autonomix Medical, Inc. Business Overview & Revenue Model

Company Description

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

How the Company Makes Money

Autonomix Medical, Inc. Financial Statement Overview

Summary

Autonomix Medical, Inc. is facing significant challenges with zero revenue and negative cash flows, despite low debt levels. The company's reliance on financing for operations poses substantial risks.

Income Statement

Autonomix Medical, Inc. is facing significant challenges with its income statement. The company reports zero total revenue across all periods, leading to negative gross profit, EBIT, and net income. The lack of revenue generation reflects a critical concern for the company's growth prospects and profitability.

Balance Sheet

The balance sheet shows a reasonable equity position with a debt-to-equity ratio indicating low leverage, which is positive. However, the equity ratio has declined over the periods, suggesting an increase in liabilities relative to assets. The company appears to maintain a low level of debt, which mitigates risk, but there is little improvement in asset growth.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, indicative of operational challenges. The company is heavily reliant on financing activities to sustain operations, which could pose risks if external funding becomes less accessible. Although capital expenditure is minimal, the negative free cash flow suggests a need for strategic adjustments.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	86.00K	0.00	0.00	0.00	0.00
Gross Profit	40.00K	-183.00K	-81.00K	0.00	0.00
EBITDA	-11.77M	-11.05M	-15.27M	0.00	752.45K
Net Income	-12.05M	-11.41M	-15.43M	-1.99M	-13.33M
Balance Sheet
Total Assets	9.00M	9.81M	9.41M	864.62K	2.05M
Cash, Cash Equivalents and Short-Term Investments	8.59M	9.14M	8.61M	864.62K	2.04M
Total Debt	0.00	0.00	1.00M	0.00	0.00
Total Liabilities	1.97M	1.71M	1.78M	220.59K	93.24K
Stockholders Equity	7.03M	8.10M	7.63M	644.03K	1.96M
Cash Flow
Free Cash Flow	-9.02M	-8.27M	-6.67M	-1.85M	-387.31K
Operating Cash Flow	-9.01M	-8.26M	-6.65M	-1.85M	-387.31K
Investing Cash Flow	-9.00K	-14.00K	-19.00K	0.00	0.00
Financing Cash Flow	10.86M	8.80M	14.41M	675.00K	2.43M

Autonomix Medical, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMIX, the sentiment is Negative. The current price of 0.8 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.10, and below the 200-day MA of 1.66, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 25.26 is Positive, neither overbought nor oversold. The STOCH value of 7.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMIX.

Autonomix Medical, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TIVC	43 Neutral	$3.92M	-0.20	-160.96%	―	-58.49%	84.67%
AMIX	40 Underperform	$5.63M	-0.14	-195.55%	―	―	65.72%
PAVM	40 Underperform	$10.04M	0.32	―	―	-73.36%	―
HSCS	38 Underperform	$7.23M	―	-193.24%	―	-66.40%	65.99%
MOVE	23 Underperform	$4.34M	-0.18	-219.60%	―	-44.84%	57.73%

Autonomix Medical, Inc. Corporate Events

Autonomix Medical Announces Positive Trial Outcomes

On April 30, 2025, Autonomix Medical, Inc. announced positive outcomes from the initial phase of its first-in-human proof-of-concept trial for treating severe pancreatic cancer pain. The trial demonstrated significant pain reduction and improved quality of life, with 100% of patients achieving zero opioid use at 7 days post-procedure. Following these results, the company plans to expand its study to include additional visceral cancers and earlier-stage pancreatic cancer, potentially doubling its addressable market.

Spark’s Take on AMIX Stock

According to Spark, TipRanks’ AI Analyst, AMIX is a Neutral.

Autonomix Medical, Inc. scores low due to severe financial performance issues, characterized by zero revenue and negative cash flows, despite low debt levels. Technical analysis shows potential short-term momentum, but a longer-term downtrend persists. Valuation is the weakest, with negative earnings and no dividend yield. The lack of earnings call data means no immediate guidance to offset these challenges, resulting in a low overall score.

To see Spark’s full report on AMIX stock, click here.